

Listing of the Claims:

Claims 1-24 (cancelled)

Claim 25 (currently amended): ~~An~~ The isolated polypeptide of ~~Claim 22~~ having at least 95% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 26 (currently amended): The isolated polypeptide of Claim 25 having at least 99% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) [the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 27 (currently amended): A chimeric polypeptide comprising a polypeptide according to Claim 22 25 fused to a heterologous polypeptide.

Claim 28 (previously presented): The chimeric polypeptide of Claim 27, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

Claims 29-34 (cancelled)

Please add the following new claims:

Claim 35 (New): An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) [the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.

Claim 36 (New): An isolated polypeptide comprising the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83).

Claim 37 (New): An isolated polypeptide comprising the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide.

Claim 38 (New): The isolated polypeptide of Claim 35 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83).

Claim 39 (New): The isolated polypeptide of Claim 35 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide.

Claim 40 (New): An isolated polypeptide comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.